Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion.
Catecholamines
Metastatic
Paraganglioma
Pheochromocytoma
Signs
Symptoms
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
21
01
2021
accepted:
05
03
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
The presence or future development of metastatic pheochromocytomas or paragangliomas (mPPGLs) can be difficult to diagnose or predict at initial presentation. Since production of catecholamines from mPPGLs is different from non-metastatic tumors (non-mPPGLs), this study aimed to clarify whether presenting catecholamine-related signs and symptoms (cSS) might also differ. The study included 249 patients, 43 with mPPGL and 206 with non-mPPGL. Clinical data at the time of biochemical diagnosis (i.e. at entry into the study) were used to generate a cumulative score of cSS for each patient. Patients with mPPGL were significantly younger (43.3 ± 14 vs. 48.9 ± 16.1 years) and included a lower proportion of females (39.5% vs. 60.7%) than patients with non-mPPGLs. Frequencies of signs and symptoms did not differ between the two groups. Patients with mPPGLs had lower (P < 0.001) urinary excretion of epinephrine (3.5 (IQR, 1.9-6.5) µg/day) than those with non-mPPGLs (19.1 (IQR, 4.3-70.2) µg/day). There was no difference in urinary excretion of norepinephrine. In patients with mPPGLs a high cSS score was associated with high urinary excretion of norepinephrine and normetanephrine. In contrast, in patients with non-mPPGLs, a high cSS was associated with high urinary excretion of epinephrine and metanephrine. Although presenting signs and symptoms were associated with production of norepinephrine in patients with mPPGLs and of epinephrine in patients with non-mPPGLs, there were no differences in signs and symptoms between the two groups. Therefore, consideration of signs and symptoms does not appear helpful for distinguishing patients with and without mPPGLs.
Sections du résumé
BACKGROUND
BACKGROUND
The presence or future development of metastatic pheochromocytomas or paragangliomas (mPPGLs) can be difficult to diagnose or predict at initial presentation. Since production of catecholamines from mPPGLs is different from non-metastatic tumors (non-mPPGLs), this study aimed to clarify whether presenting catecholamine-related signs and symptoms (cSS) might also differ.
METHODS
METHODS
The study included 249 patients, 43 with mPPGL and 206 with non-mPPGL. Clinical data at the time of biochemical diagnosis (i.e. at entry into the study) were used to generate a cumulative score of cSS for each patient.
RESULTS
RESULTS
Patients with mPPGL were significantly younger (43.3 ± 14 vs. 48.9 ± 16.1 years) and included a lower proportion of females (39.5% vs. 60.7%) than patients with non-mPPGLs. Frequencies of signs and symptoms did not differ between the two groups. Patients with mPPGLs had lower (P < 0.001) urinary excretion of epinephrine (3.5 (IQR, 1.9-6.5) µg/day) than those with non-mPPGLs (19.1 (IQR, 4.3-70.2) µg/day). There was no difference in urinary excretion of norepinephrine. In patients with mPPGLs a high cSS score was associated with high urinary excretion of norepinephrine and normetanephrine. In contrast, in patients with non-mPPGLs, a high cSS was associated with high urinary excretion of epinephrine and metanephrine.
CONCLUSION
CONCLUSIONS
Although presenting signs and symptoms were associated with production of norepinephrine in patients with mPPGLs and of epinephrine in patients with non-mPPGLs, there were no differences in signs and symptoms between the two groups. Therefore, consideration of signs and symptoms does not appear helpful for distinguishing patients with and without mPPGLs.
Identifiants
pubmed: 35201450
doi: 10.1007/s12672-021-00404-x
pii: 10.1007/s12672-021-00404-x
pmc: PMC8777503
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© 2021. The Author(s).
Références
Hypertension. 2000 Dec;36(6):1045-52
pubmed: 11116123
Eur J Endocrinol. 2015 Sep;173(3):377-87
pubmed: 26060051
Cancer Res. 2003 Sep 1;63(17):5615-21
pubmed: 14500403
Clin Chem Lab Med. 2020 Oct 01;59(2):353-363
pubmed: 33001846
Endocr Regul. 2018 Jan 1;52(1):41-54
pubmed: 29453919
Pediatr Blood Cancer. 2017 Nov;64(11):
pubmed: 28409892
Clin Chim Acta. 2019 Mar;490:46-54
pubmed: 30571948
Eur J Endocrinol. 2019 Oct;181(4):409-420
pubmed: 31370000
Front Endocrinol (Lausanne). 2020 Feb 18;11:61
pubmed: 32132978
Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311, vii
pubmed: 21565668
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2367-2374
pubmed: 30715419
Ann Surg Oncol. 2017 Nov;24(12):3624-3630
pubmed: 28884434
Eur J Clin Invest. 2015 Sep;45(9):986-97
pubmed: 26183460
Endocr Relat Cancer. 2010 Dec 21;18(1):97-111
pubmed: 21051559
Am J Cancer Res. 2020 Mar 01;10(3):769-780
pubmed: 32266090
Endocrine. 2008 Aug-Dec;34(1-3):96-100
pubmed: 18982461
Endocr Pract. 2016 Mar;22(3):302-14
pubmed: 26523625
Endocr Relat Cancer. 2020 Nov;27(11):625-640
pubmed: 33112842
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31614368
Genet Med. 2018 Dec;20(12):1652-1662
pubmed: 30008476
Endocr Relat Cancer. 2004 Sep;11(3):423-36
pubmed: 15369446
Clin Chim Acta. 2013 Mar 15;418:50-8
pubmed: 23313054
PLoS One. 2015 May 06;10(5):e0125426
pubmed: 25946206
J Oncol. 2012;2012:872713
pubmed: 22851969
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Eur J Cancer. 2012 Jul;48(11):1739-49
pubmed: 22036874
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305
pubmed: 28605453
Int J Cancer. 2014 Nov 1;135(9):2054-64
pubmed: 24676840
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1223-33
pubmed: 18854424